Last updated on September 2017

A randomized, double-blind, placebo-controlled, phase 2b dose-ranging study to asses the efficacy and safety of OBE2109 in subjects with endometriosis associated pain.


Brief description of study

A randomized, double-blind, placebo-controlled, phase 2b dose-ranging study to asses the efficacy and safety of OBE2109 in subjects with endometriosis associated pain.

Detailed Study Description

The study is a prospective, dose-finding, randomized, parallel group, double-blind, placebo-controlled phase 2b study investigating the efficacy and safety of OBE2109 in the treatment of 330 women with moderate-to-severe endometriosis associated pain.

Clinical Study Identifier: TX15604

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Betsy Moclair

Manhattan Medical Research
New York, NY USA
  Connect »